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 Zika virus (ZIKV) is a member of the Flaviviridea family comprising ca. 70 viruses 
sharing common structural features, and takes its name from the Zika Forest in Uganda 
where it was first isolated (Dick, 1953; Dick et al., 1952). It is the causative agent of an 
emerging infection arising from bites of the Aedes aegypti species for which, as yet, the full 
implications for human health remain unclear. Widespread infection and serious birth 
defects, including neurological diseases and microcephaly in Brazil have been reported 
(Rasmussen et al., 2016). In adults, ZIKV infection has been epidemiologically linked to 
increased prevalence of Guillain-Barré Syndrome (Cao-Lormeau et al., 2016; Parra et al., 
2016). Thus, both in utero and adult, ZIKV-associated pathological conditions suggest that 
the virus could infect nerves (Bell et al., 1971) and neural cells (Garcez et al., 2016). 
Additional modes of transmission to mosquito bites have also emerged, including sexual 
transmission (D'Ortenzio et al., 2016; Foy et al., 2011; Musso et al., 2015) and blood 
transfusion (Motta et al., 2016). These could further expand the epidemic impact of ZIKV 
infection, increasing the need for an effective vaccine, and antiviral agents with which to 
treat infected individuals. 
 Conventional antiviral drug-discovery pipelines involve complex, expensive, and time-
consuming processes, militating against their rapid and widespread deployment, particularly 
in developing countries. One attractive alternative for combating emerging and rapidly 
spreading infectious diseases is drug repurposing (Cheng et al., 2016), the application of an 
existing licensed pharmaceutical agent for another medical need. This has already been 
proposed for the treatment of both hepatitis C (He et al., 2015) and Ebola virus (Sakurai et 
al., 2015) infections. Heparin, the widely used anticoagulant, has potentially attractive 
features including activity against attachment and entry of the enveloped viruses, human 
simplex (HSV) (Herold et al., 1996; Nahmias and Kibrick, 1964), human immunodeficiency 
(HIV) (Baba et al., 1988), SARS coronavirus (Vicenzi et al., 2004), and influenza (H5N1) 
(Skidmore et al., 2015). Here, we explore the effects of heparin on ZIKV infection in human 
neural progenitor cells (hNPCs) with particular regard to virus replication and induction of 
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cytopathic effects resulting in cell death. 
 Cells:- Human neural progenitor cells (hNPCs) were obtained by the reprogramming 
of human adult skin fibroblasts (Movement Disorders Bio-Bank, Carlo Besta Institute, Milan, 
Italy) and were reprogrammed (CytoTune-iPS 2.0 Sendai Kit, Life Technologies) to obtain 
human induced pluripotent stem cells (hiPSCs), then maintained in feeder-free conditions 
(mTeSR1 culture medium, Stem Cell Technologies), as reported (Orellana et al., 2016). For 
embryoid bodies (EBs), dissociated hiPSCs were seeded into low-adhesion plates in 
mTeSR1 medium supplemented with N2 (1:200), ThermoFisher Scientific), human Noggin 
(0.5 µg/ml, R&D System), SB431542 (5 µM, Sigma), Y27632 (10 µM, Miltenyi Biotec) and 
penicillin-streptomycin (100 µg/ml, Sigma). For rosettes, EBs were plated after 10 days onto 
matrigel-coated plates (1:100, matrigel growth factor reduced, Corning) in DMEM/F12 
(Sigma) with N2 (0.5%), non-essential amino acids (1%, ThermoFisher Scientific) and 
penicillin-streptomycin. After 10 days, cells were passaged with Accutase (Sigma) and 
seeded onto matrigel coated-flasks in media containing DMEM/F12, N2 (0.5%), B27 (0.5%), 
ThermoFisher Scientific), penicillin-streptomycin (1%) and basic fibroblast growth factor 
(FGF)2 (20 ng/ml, ThermoFisher Scientific).  
Viruses:- The viruses employed were the historical ZIKV strain (MR766), (EVAg - 
European Virus Archive), or recent Brazilian strain (INMI-1; GenBank Accession # 
KU991811), isolated from an Italian citizen who had travelled in Brazil in January 2016. Both 
viral strains were expanded in Vero cells and titered in a Plaque Forming Assay (PFA) 
(Hamel et al., 2015). 
Infection:- Cells were seeded at 3 x 104 / ml in 48 well plates. After 3 days of culture, 
heparin (Celsus, Cincinnati) was added 1 h prior to infection at 100 µg/ml and then virus- 
containing supernatant was added, providing multiplicity of infection (moi) of 1. The 
efficiency of infection was evaluated by immunofluorescence staining with either an anti-
flavivirus envelope monoclonal antibody (mAb) (Millipore, mAb 10216) or a double-stranded 
RNA (1:300, English and Scientific Consulting Kft, Hungary) 3 and 7 days post-infection. To 
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evaluate apoptosis, an Ab against cleaved-caspase-3 (1:200, Cell Signaling, 9661) was 
used. Cells were then washed with PBS and incubated for 1 h with Hoechst and either anti-
mouse Alexa Fluor-488 or anti-rabbit Alexa Fluor-594 secondary Abs (1:1,000 in blocking 
solution, ThermoFisher Scientific). Viral supernatants were collected and viral titers were 
determined in the PFA. Cell death was detected in 10 µl samples of culture supernatant 
transferred into half-black 96 microwell plates (Costar). To each well, 50 µl of adenylate 
kinase detection reagent (ToxiLight® BioAssay, Lonza) was added and the plate incubated 
(10 min, room temperature). Luminescence was measured in a Mithras LB940 Microplate 
Reader (Berthold Technologies). 
Immunofluorescence staining with Nestin (a neuroectodermal stem cell marker) and 
SOX2 (a transcription factor maintaining pluripotency or self-renewal) confirmed the nature 
of the hNPCs employed (Figure 1A, upper panels). hNPCs were incubated with heparin 
(100 µg/ml, 1 h prior to infection (see Supplementary Table 1 for details of heparin 
characterization and 1H and 13C NMR spectra in Supplementary Figures 2 and 3) with 
historical ZIKV strain MR766 and recent Brazilian strain, INMI-1. The proportion of MR766 
infected hNPCs was ca. 60% (Figures 1A, middle panels). Modest decreases (not 
statistically significant) in infected cell numbers were observed in cultures pretreated with 
heparin. Progeny infectious virion production was measured in culture supernatants using 
standard PFA on Vero cells, indicating that heparin reduced the production of progeny virus 
by 2-3 fold (Figure 1A, lower panels).  
 We next evaluated the effect of heparin on hNPCs infection by the INMI-1 strain, which 
is characterized by lower virus replication efficiency (35%) than MR766. Nonetheless, the 
antiviral effect of heparin was modest and, as for MR766, not statistically different from 
untreated cultures, as determined by quantification of infection efficiency and viral titers 
released into the culture supernatant in the PFA on Vero cells (Figure 1B, lower panels).  
 Then, we analyzed the virus-induced cytopathic effects by measuring the levels of 
adenylate kinase released into the culture supernatant after damage of the cell membrane 
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(Crouch et al., 1993; Olsson et al., 1983). Heparin did not exert toxic effects on uninfected 
cells (Figure 2). Unexpectedly and strikingly, however, heparin fully prevented the virus-
induced cytopathic effects of cultures infected with either the MR766 or INMI-1 ZIKV strains 
(Figure 2A and B, respectively). Thus, heparin partially uncoupled the virus replication (that 
was only modestly inhibited) from the virus-induced death of hNPCs.  
 ZIKV infection of cranial neural crest cells has been linked to the release of vascular 
endothelial growth factor (VEGF) and leukaemia inhibitory factor (LIF) exerting proapoptotic 
effects on adjacent cells (Bayless et al., 2016). Thus, we determined the proportion of cells 
that were positive for caspase-3 staining, as an indicator of apoptotic cell death (Lavrik, 
2005). The proportion of caspase-3+ cells in uninfected and untreated cell cultures increased 
from 9.5 ± 3.4% at day 3 after infection (day 6 after the initial seeding) to 29 ± 1.1% 7 days 
after infection. At the same time points, heparin decreased the proportion of caspase-3+ cells 
to 5.9 ± 2.7% and 12.1 ± 3.7%, respectively. In infected cultures, the proportion of caspase-
3+ cells increased to 31.1 ± 5.5% 7 days post-infection with the INMI-1 strain, and decreased 
to 16.2 ± 0.3% with heparin (data not shown). These results suggest that the activation of 
the master executor of apoptosis, i.e. caspase-3, is activated in hNPC cultures 
independently of virus infection and that heparin probably prevents its activation by 
stabilizing FGF2 for the duration of the culture, as reported (Caldwell et al., 2004). In 
contrast, heparin fully prevented virus-induced necrotic death of cells, as measured by the 
release of adenylate kinase in the culture supernatant (Figure 2), although the mechanism 
of action remains unknown. As the culture condition induced the apoptosis of uninfected 
hNPCs, we tested whether heparin affected ZIKV cytopathic effects, and in particular, 
prevented caspase-3 activation in Vero cells that are highly permissive to ZIKV replication. 
The background level of apoptosis in the absence of viral infection was negligible 
(Supplementary Figure 1). Indeed, heparin treatment did not alter the levels of viral 
replication as compared with control cells in Vero cells, however, it significantly decreased 
the percentage of caspase-3+ cells suggesting that heparin can also prevent ZIKV-induced 
apoptosis. 
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 In terms of drug repurposing, in addition to caspase-3 inhibitors (Cheng et al., 2016; 
He et al., 2015), heparin represents both a clinically-approved pharmacological agent 
capable of preventing ZIKV-induced necrosis of neural cells, as observed with hNPCs, and a 
lead compound to help discover novel agents preventing virus replication and cytopathic 
effects.  
 Independently of the obvious heparin anticoagulant effect, there is now considerable 
evidence that heparin possesses anti-inflammatory, anti-apoptotic and proliferative activities 
that rely on a variety of mechanisms (Katsi et al., 2016). However, the polyanionic nature of 
heparin favours the neutralization of cationic mediators of inflammation and apoptosis but, 
also viral envelopes (Rusnati et al., 2009). The mechanism through which heparin 
derivatives inhibit infectivity in other viral infections, such as herpes simplex virus (Shukla 
and Spear, 2001), is most likely by competing with host cell surface glycoproteins or 
proteoglycans, or in other cases, through binding of low specificity to several proteins by 
virtue of their polyanionic nature (Skidmore et al., 2015). In the present case, however, the 
effect of heparin on infectivity is less striking than its ability to protect infected cells from cell 
death. The most likely mechanism to explain this phenomenon is that heparin is binding 
several proteins that promote inflammation and cell death. Heparin has been documented to 
bind and, in many cases neutralise, a range of relevant growth factors and enzymes, 
including tissue necrosis factor-α (TNF-α) (Salas et al., 2000; Spratte et al., 2013; Veraldi et 
al., 2015). 
In conclusion, heparin is used safely during pregnancy and could serve as a potential 
adjunct therapy in the presence or likelihood of ZIKV infection. While ultra-low molecular 
weight heparin has been reported to cross the blood brain barrier (FDA guidelines, accessed 
05/10/2016), heparin does not cross the placenta 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm219000.htm. Improved delivery 
systems may facilitate the administration of heparin and heparin derivatives.  
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Figure 1. Heparin does not inhibit ZIKV infection of hNPCs 
A. Infection of hNPCs with the MR766 strain with (middle two panels) and without 
(upper two panels) heparin treatment (100 µg/ml). To determine that the cells were bona fide 
hNPCs, cells were stained with Sox2 (red), Nestin (green) and Hoechst (blue). Uninfected 
and infected cells were fixed after 3 days with paraformaldehyde solution and stained with a 
mAb specific for Flavivirus E protein (green). After PBS washes, cells were washed again, 
mounted and examined by microscopy. Quantification of infection efficiency and viral titers 
released into the culture supernatant are reported in the two lower panels (left and right, 
respectively). Scale bar of upper left panel: 20 µm, scale bar of remaining panels: 5 µm. Bar 
graphs indicate the mean ± SEM of 4 independent experiments. P values were calculated by 
Student’s paired t-test.  
 B. Infection of hNPCs by the INMI-1 strain, with (middle two panels) or without (upper 
panel) heparin treatment (100 µg/ml). Uninfected and infected cells were fixed after 7 days 
with paraformaldehyde solution and stained with a mAb specific for Flavivirus E protein 
(green). Quantification of infection efficiency and viral titers released into the culture 
supernatant are reported in the lower two panels (left and right, respectively). Scale bar: 5 
µm. Bar graphs indicate the mean ± SEM of 2 fields including more than 1,000 cells in 3 
independent experiments. P values were calculated by Student’s paired t-test. 
 
Figure 2. Heparin prevents virus-induced CPE 
A. Supernatant of infected hNPCs with the MR766 strain was collected 3 days post infection. 
The results are expressed as relative luminescent unit (RLU). Data are expressed as mean 
± SEM of 3 independent experiments. Repeated measures Anova was used with the 
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Bonferroni correction. *Represents statistical comparison among groups (**, p<0.01; *, 
p<0.05). B. Supernatant of infected hNPCs with the INMI-1 strain was collected 7 days post 
infection. The cell death was analyzed as reported in A. Results are expressed as relative 
luminescent unit (RLU). Data represent the mean ± SEM of 3 independent experiments. 
Repeated Measures ANOVA was used with the Bonferroni correction. *Represents 
statistical comparison among groups (**, p<0.01; *, p<0.05). 
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Highlights 
 
·Recent outbreak of Zika virus in Brazil included widespread neurological effects 
·One approach to tackling emerging infection is to re-purpose existing pharmaceuticals 
·The anticoagulant, heparin, inhibits infection weakly, but completely prevents cell death 
 
